News & Updates
Filter by Specialty:
Is prior allergy a deal-breaker for COVID-19 vacc?
A large prospective, observational study has suggested that while individuals with a history of high-risk allergy may have an increased risk of allergic reactions following receipt of a messenger RNA (mRNA) COVID-19 vaccine, they are still able to receive both vaccine doses.
Is prior allergy a deal-breaker for COVID-19 vacc?
13 Dec 2021Saliva outperforms nasopharyngeal swabs for COVID-19 detection
Compared with nasopharyngeal swabs (NPS), saliva samples provide higher diagnostic yield for detecting positivity to the coronavirus disease 2019 (COVID-19), a recent study has found.
Saliva outperforms nasopharyngeal swabs for COVID-19 detection
13 Dec 2021Short-course, high-dose gatifloxacin gets a pass in multidrug-resistant TB with caveat
A short-term treatment regimen based on high-dose gatifloxacin appears to be effective against multidrug- or rifampicin-resistant tuberculosis (TB) but at the cost of increased severe adverse drug reactions, as shown in a study.
Short-course, high-dose gatifloxacin gets a pass in multidrug-resistant TB with caveat
08 Dec 2021MRNA COVID-19 vaccines weaker in patients with autoimmune systemic diseases
Patients with autoimmune systemic diseases (ASD) are less likely to produce an immune response following inoculation with mRNA vaccines against the coronavirus disease 2019 (COVID-19), according to a recent study.